RSS   Newsletter   Contact   Advertise with us

Roche and Illumina partner to broaden patient access to genomic testing

Share on Twitter Share on LinkedIn
Christian Fernsby ▼ | January 14, 2020
Roche announced that it has entered into a 15-year, non-exclusive partnership with Illumina to broaden the adoption of distributable next-generation sequencing (NGS) based testing in oncology.
Illumina
Medicine and business   Illumina
As the understanding of the genomic drivers of cancer evolves, NGS has the potential to transform cancer risk prediction, detection, diagnosis, treatment and monitoring.

Topics: Roche Illumina

This agreement brings together complementary capabilities of each company to broaden global adoption of NGS in cancer care.

As part of the agreement, Illumina will grant Roche rights to develop and distribute in vitro diagnostic (IVD) tests on Illumina’s NextSeq 550Dx System, as well as on its future portfolio of diagnostic (Dx) sequencing systems.

Roche will in turn collaborate with Illumina to complement Illumina’s comprehensive pan-cancer assay TruSight Oncology 500 (TSO 500) with new companion diagnostic (CDx) claims.

The financial terms of the deal were not disclosed.

Under the IVD terms of the agreement, Roche will develop, manufacture and commercialise AVENIO IVD tests for both tissue and blood for use on Illumina’s NextSeq 550Dx System.

Illumina will continue to sell the NextSeq 550Dx Systems and core sequencing consumables.

Under the CDx terms of the agreement, Roche and Illumina will develop and pursue CDx claims on TSO 500 for both existing and pipeline Roche oncology targeted therapies on the NextSeq 550Dx System.

Illumina will lead the development and regulatory approval process and will continue to manufacture, supply and commercialise TSO 500.

Roche will support the development of the claims and regulatory filings.


 

MORE INSIDE POST